Department of Pharmacology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Rev Recent Clin Trials. 2024;19(4):256-266. doi: 10.2174/0115748871301446240513093612.
Most of the mortality after Heart Transplantation (HT) is attributed to severe cardiac allograft vasculopathy (CAV) and rejection.
This meta-analysis aimed to investigate the effects of postoperative statin therapy on outcomes (mortality, rejection, and CAV in HT patients).
This systematic review and meta-analysis was performed on publications between 1980 and October 2023 in Web of Science, Scopus, PubMed, Cochrane, Science Direct, Google Scholar, and Embase databases. Heterogeneity was assessed using Chi-square, I2, and forest plots. Publication bias was evaluated using Begg's and Egger's tests. Analyses were performed in Stata 15 with significance at p < 0.05.
This meta-analysis included 17 studies comprising 4,627 participants and conducted between 1995 to 2021. Compared to non-users, the odds of mortality were lower among statin users (OR= 0.49, 95% CI: 0.32-0.75, p < 0.001). The odds of CAV were also reduced with statin use (OR= 0.71, 95% CI: 0.53-0.96, p = 0.027). The odds of rejection were not significantly different (OR= 0.69, 95% CI: 0.41-1.15, p = 0.152). However, rejection odds were lower with statins in RCTs (OR= 0.42, 95% CI: 0.21-0.82, p = 0.012) but not in case-control studies (OR= 0.87, 95% CI: 0.49-1.52, p = 0.615). No publication bias was observed with Begg's test, but Egger's test showed possible bias.
This meta-analysis found postoperative statin use associated with lower mortality and CAV, but not overall rejection, though RCT subgroup analysis showed decreased rejection with statins. Statin therapy may improve prognosis in HT patients.
心脏移植(HT)后大多数死亡归因于严重的心脏移植物血管病(CAV)和排斥反应。
本荟萃分析旨在研究术后他汀类药物治疗对 HT 患者结局(死亡率、排斥反应和 CAV)的影响。
本系统评价和荟萃分析检索了 1980 年至 2023 年 10 月间在 Web of Science、Scopus、PubMed、Cochrane、Science Direct、Google Scholar 和 Embase 数据库中的出版物。使用卡方检验、I2 和森林图评估异质性。使用贝叶斯和埃格检验评估发表偏倚。分析使用 Stata 15 进行,p<0.05 为差异有统计学意义。
本荟萃分析纳入了 17 项研究,共计 4627 名参与者,研究时间为 1995 年至 2021 年。与非使用者相比,他汀类药物使用者的死亡率较低(OR=0.49,95%CI:0.32-0.75,p<0.001)。使用他汀类药物也降低了 CAV 的发生率(OR=0.71,95%CI:0.53-0.96,p=0.027)。排斥反应的发生率无显著差异(OR=0.69,95%CI:0.41-1.15,p=0.152)。然而,RCT 中的他汀类药物降低了排斥反应的发生率(OR=0.42,95%CI:0.21-0.82,p=0.012),而病例对照研究中则没有(OR=0.87,95%CI:0.49-1.52,p=0.615)。贝叶斯检验未发现发表偏倚,但埃格检验显示可能存在偏倚。
本荟萃分析发现术后他汀类药物治疗与死亡率和 CAV 降低相关,但与总体排斥反应无关,尽管 RCT 亚组分析显示他汀类药物可降低排斥反应。他汀类药物治疗可能改善 HT 患者的预后。